Comprehensive proteogenomic characterization of rare kidney tumors.
Cell Rep Med
; 5(5): 101547, 2024 May 21.
Article
in En
| MEDLINE
| ID: mdl-38703764
ABSTRACT
Non-clear cell renal cell carcinomas (non-ccRCCs) encompass diverse malignant and benign tumors. Refinement of differential diagnosis biomarkers, markers for early prognosis of aggressive disease, and therapeutic targets to complement immunotherapy are current clinical needs. Multi-omics analyses of 48 non-ccRCCs compared with 103 ccRCCs reveal proteogenomic, phosphorylation, glycosylation, and metabolic aberrations in RCC subtypes. RCCs with high genome instability display overexpression of IGF2BP3 and PYCR1. Integration of single-cell and bulk transcriptome data predicts diverse cell-of-origin and clarifies RCC subtype-specific proteogenomic signatures. Expression of biomarkers MAPRE3, ADGRF5, and GPNMB differentiates renal oncocytoma from chromophobe RCC, and PIGR and SOSTDC1 distinguish papillary RCC from MTSCC. This study expands our knowledge of proteogenomic signatures, biomarkers, and potential therapeutic targets in non-ccRCC.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Carcinoma, Renal Cell
/
Biomarkers, Tumor
/
Proteogenomics
/
Kidney Neoplasms
Limits:
Female
/
Humans
/
Male
/
Middle aged
Language:
En
Journal:
Cell Rep Med
Year:
2024
Type:
Article
Affiliation country:
United States